寡转移性前列腺癌观察与立体定向消融放疗的随机二期试验
ORIOLE二期随机试验纳入54例激素敏感复发性寡转移前列腺癌患者,按2:1随机接受SABR或观察。
要点
- SABR显著改善6个月进展率和无进展生存期,且≥3级毒性未观察到。
- PSMA靶向PET完全巩固病灶可进一步降低新病灶风险。
- SABR诱导系统性免疫反应,基线免疫特征可能预测获益。
核心结论
- SABR改善寡转移性前列腺癌的肿瘤学结局,PSMA靶向PET完全巩固病灶可增强疗效。
- SABR诱导系统性免疫反应,基线免疫表型和肿瘤突变状态可能预测SABR获益。
研究设计与样本
- ORIOLE为二期随机研究,2016年5月至2018年3月从3家美国放疗机构入组,数据截止2019年5月20日。
- 筛查80例,随机54例激素敏感复发性前列腺癌且常规影像可检出1-3个转移灶、入组前6个月内未用ADT或总ADT使用<3年的患者。
- 患者按2:1随机接受SABR或观察。
主要发现
- 未观察到≥3级毒性效应。
关键数值与推荐
- 主要终点为6个月进展,定义为PSA升高、常规影像进展、症状进展、因任何原因启动ADT或死亡。
- 预设次要结局包括SABR毒性、6个月局部控制、无进展生存期、Brief Pain Inventory(短表)测量的生活质量、常规影像与PSMA靶向PET识别转移性疾病的一致性。
临床怎么用
- 对激素敏感复发性寡转移前列腺癌患者,SABR可作为延迟ADT启动的策略。
- PSMA靶向PET完全巩固病灶可能增强SABR疗效,提示整合PSMA靶向PET评估的重要性。
- 基线免疫表型和肿瘤突变状态可能帮助筛选SABR获益人群。
局限性
- 样本量较小(54例),二期试验结果需更大规模验证。
- 随访时间有限,长期生存获益未报告。
- 免疫相关分析为探索性,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation of androgen deprivation therapy (ADT). OBJECTIVE: To determine if stereotactic ablative radiotherapy (SABR) improves oncologic outcomes in men with oligometastatic prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) phase 2 randomized study accrued participants from 3 US radiation treatment facilities affiliated with a university hospital from May 2016 to March 2018 with a data cutoff date of May 20, 2019, for analysis. Of 80 men screened, 54 men with recurrent hormone-sensitive prostate cancer and 1 to 3 metastases detectable by conventional imaging who had not received ADT within 6 months of enrollment or 3 or more years total were randomized. INTERVENTIONS: Patients were randomized in a 2:1 ratio to receive SABR or observation. MAIN OUTCOMES AND MEASURES: The primary outcome was progression at 6 months by prostate-specific antigen level increase, progression detected by conventional imaging, symptomatic progression, ADT initiation for any reason, or death. Predefined secondary outcomes were toxic effects of SABR, local control at 6 months with SABR, progression-free survival, Brief Pain Inventory (Short Form)-measured quality of life, and concordance between conventional imaging and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography in the identification of metastatic disease. RESULTS: In the 54 men randomized, the median (range) age was 68 (61-70) years for patients allocated to SABR and 68 (64-76) years for those allocated to observation. Progression at 6 months occurred in 7 of 36 patients (19%) receiving SABR and 11 of 18 patients (61%) undergoing observation (P = .005). Treatment with SABR improved median progression-free survival (not reached vs 5.8 months; hazard ratio, 0.30; 95% CI, 0.11-0.81; P = .002). Total consolidation of PSMA radiotracer-avid disease decreased the risk of new lesions at 6 months (16% vs 63%; P = .006). No toxic effects of grade 3 or greater were observed. T-cell receptor sequencing identified significant increased clonotypic expansion following SABR and correlation between baseline clonality and progression with SABR only (0.082085 vs 0.026051; P = .03). CONCLUSIONS AND RELEVANCE: Treatment with SABR for oligometastatic prostate cancer improved outcomes and was enhanced by total consolidation of disease identified by PSMA-targeted positron emission tomography. SABR induced a systemic immune response, and baseline immune phenotype and tumor mutation status may predict the benefit from SABR. These results underline the importance of prospective randomized investigation of the oligometastatic state with integrated imaging and biological correlates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02680587.
引用
- Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32215577. doi:10.1001/jamaoncol.2020.0147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。